XBiotech Inc/ CA98400H1029 /
2024-04-17 10:00:00 PM | Chg. -0.8500 | Volume | Bid10:08:41 AM | Ask10:08:41 AM | High | Low |
---|---|---|---|---|---|---|
8.1100USD | -9.49% | 81,922 Turnover: 492,093.0851 |
6.6000Bid Size: 100 | 12.9700Ask Size: 200 | 9.1900 | 8.0250 |
GlobeNewswire
2023-11-14
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
GlobeNewswire
2023-09-26
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate T...
GlobeNewswire
2023-08-30
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natr...
GlobeNewswire
2022-01-26
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natr...
GlobeNewswire
2021-09-08
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in ...
GlobeNewswire
2021-08-30
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
GlobeNewswire
2021-06-23
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of P...
GlobeNewswire
2021-05-03
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptiv...
GlobeNewswire
2021-04-19
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled S...
GlobeNewswire
2021-01-21
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
GlobeNewswire
2021-01-19
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
GlobeNewswire
2020-11-19
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influen...
GlobeNewswire
2020-09-21
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co...